QUANTITATIVE ONCOLOGY Paul Spellman, PhD and Joe Gray, PhD, Program Co-Leaders ABSTRACT The Quantitative Oncology (QO) Program is a multi-disciplinary research program that was formed to facilitate the development and application of advanced measurement capabilities from omics to imaging, combined with computational techniques, to improve cancer management. The goal of the QO program is to enable quantitative understanding of the behavior of cancerous cells and tissues as they evolve, respond to therapy, and interact with their microenvironments. The QO program facilitates collaborative science organized around three research themes: 1) Imaging ? focuses on improving the understanding of cancer by analyzing components of tumors on scales from angstrom to centimeters, including proteins to cells to tissues and using this data to inform diagnostics and therapies; 2) Omics ? employing and improving tools to analyze genomes, transcriptomes, and proteomes to enhance our understanding of cancer; and 3) Systems Biology - focuses on elucidation of the emergent properties of cancer-related molecular networks, the molecular and cellular phenotypes they regulate and the evolution/adaptation of these systems during cancer development and treatment. The QO Program is co-led by Paul Spellman, PhD, an expert in the application of translational cancer genomics and systems biology to cancer detection and classification, and Joe Gray, PhD, an expert in systems biomedicine and imaging technologies, with an emphasis on breast and pancreatic cancer. The QO program has 28 members who are drawn from seven basic science departments and four clinical departments in the OHSU School of Medicine, and the Pacific Northwest National Laboratory (PNNL). Annual direct cost funding as of January 2016 amounted to $10,011,427 (total cost), of which $1,833,130 (total cost) was from the NCI and $6,229,652 (total cost) was peer-reviewed. The discoveries made in this program have resulted in 251 publications, of which 31.5% are intra-programmatic collaborations, 43.8% are inter-programmatic collaborations, and 71.3% are inter- institutional.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-22
Application #
9968127
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6

Showing the most recent 10 out of 277 publications